News | July 22, 2023
Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Lutio has the potential to offer significant cost savings when available to UK patients.
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
